Cangrelor in Comatose Survivors of OHCA Undergoing Primary PCI (NCT04005729) | Clinical Trial Compass
CompletedPhase 4
Cangrelor in Comatose Survivors of OHCA Undergoing Primary PCI
Slovenia30 participantsStarted 2019-07-01
Plain-language summary
The main objective of the trial is to find out if 4-hour continuous infusion of parenteral P2Y12 inhibitor cangrelor at the start of primary percutaneous coronary intervention (PCI) immediately and effectively suppresses platelet activity in comatose survivors of out-of-hospital cardiac arrest (OHCA). Half of the participants will receive the standard care of dual antiplatelet therapy - acetysalicylic acid and ticagrelor tablets via nasogastric or orogastric tube and the other half the standard care with additional cangrelor infusion at the start of the PCI.
Who can participate
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* age 18 to 70 years
* comatose survivors of out-of-hospital cardiac arrest undergoing primary percutaneous coronary intervention
* treatment with induced therapeutic hypothermia
* no contraindication for dual antiplatelet therapy
Exclusion Criteria:
* pregnancy
* patients without return of spontaneous circulation or patients on ECMO
* history of recent P2Y12 use (last 7 days)
* history of recent vitamin K antagonist or NOAC use (last 14 days)
* active bleeding
* history of transient ischemic attack or cerebral vascular insult
* strong bleeding tendency (Child C liver cirrhosis, stage IV-V chronic renal disease)
* history of allergic reactions to acetylsalicylic acid, heparin or P2Y12 inhibitors
* terminal disease or life expectancy less than 1 year
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
VerifyNow P2Y12Test - Platelet Reactivity
Timeframe: 1 hour after the start of cangrelor infusion/1 hour after the start of PPCI in controls
2
VerifyNow P2Y12Test - Platelet Reactivity
Timeframe: 3 hours after the start of cangrelor infusion/3 hours after the start of PPCI in controls
3
VerifyNow P2Y12Test - Platelet Reactivity
Timeframe: 5 hours after the start of cangrelor infusion/5 hours after the start of PPCI in controls
4
Multiplate ADP test
Timeframe: 1 hour after the start of cangrelor infusion/1 hour after the start of PPCI in controls
5
Multiplate ADP test
Timeframe: 3 hours after the start of cangrelor infusion/3 hours after the start of PPCI in controls
6
Multiplate ADP test
Timeframe: 5 hours after the start of cangrelor infusion/5 hours after the start of PPCI in controls
7
BARC score or the need for discontinuation of cangrelor infusion